Siltuximab (CNTO-328)

Name	Value
Weight	0.000 N/A
Zinc ID	N/A
Smiles	N/A
Molecular formula	N/A
Mode of inhibition	Monoclonal antibody to IL6R; JAK/STAT inhibitor
CAS	541502-14-1

Clinical Trials

Show entries

Search:

Study title	Status	Conditions	Link
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma	Terminated	Multiple Myeloma	NCT01309412
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma	Withdrawn	Multiple Myeloma	NCT01266811
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)	Terminated	Cancer, Prostate	NCT00385827
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors	Completed	Ovarian Neoplasms\|Pancreatic Neoplasms\|Colorectal Neoplasms\|Head and Neck Neoplasms\|Lung Neoplasms	NCT00841191
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome	Terminated	Myelodysplastic Syndrome	NCT01513317
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma	Completed	Monoclonal Gammopathy of Undetermined Significance\|Multiple Myeloma\|Plasma Cell Neoplasm	NCT01219010
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma	Completed	High-risk Smoldering Multiple Myeloma	NCT01484275
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	Completed	Multiple Myeloma	NCT00401843
A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants	Completed	Healthy	NCT02074800
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients	Completed	Multiple Myeloma	NCT00911859

Showing 1 to 10 of 23 entries

Previous1 2 3Next

References

Show entries

Search:

Publication	DOI	Pubmed	PMCID
No data available in table

Showing 0 to 0 of 0 entries

Filter data

Compound	Siltuximab (CNTO-328)
Experiment types
Concentrations
Cell lines
Organisms
Animal models
STAT proteins
Other

Experiments

Show entries

Search:

Compound	Experiment type	Investigated event	Concentration	Cell line	Organism	Animal model	Stat protein	Details
No data available in table

Showing 0 to 0 of 0 entries